Recent News

• 09.10.2025 - Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.21.2025 - Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
• 08.21.2025 - Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
• 08.21.2025 - Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
• 08.11.2025 - Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.11.2025 - Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.11.2025 - Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.07.2025 - Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
• 08.07.2025 - Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
• 08.07.2025 - Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 09.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2025 - 144 Report of proposed sale of securities
• 08.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.22.2025 - 144 Report of proposed sale of securities
• 08.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.20.2025 - 144 Report of proposed sale of securities
• 08.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - 8-K Current report